Validation of MMS Test for Cancer Monitoring (MMS-TM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02113683
Recruitment Status : Terminated (insufficient recruitment on the part of clinic; study will not resume)
First Posted : April 15, 2014
Last Update Posted : June 21, 2018
Helios Klinikum Berlin-Buch
Information provided by (Responsible Party):
MedInnovation GmbH

Brief Summary:
The purpose of this study is the validation of MMS test to detect active tumor growth in different cancer types before and after therapy, as well as in the course of therapy and for subsequent relapse control compared to standard methods (clinical examination, imaging, tumor markers). It should be consider whether the MMS test has comparable diagnostic accuracy, and thus can replace more expensive or invasive procedures in future.

Condition or disease
Colo-rectal Cancer Stomach Cancer Melanoma Sarcoma

Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Validation of MMS Test to Detect Active Tumor Growth of Different Cancer Types Before and After Therapy, as Well as for Subsequent Relapse Control in Comparison to Conventional Methods
Study Start Date : May 2014
Actual Primary Completion Date : June 20, 2018
Actual Study Completion Date : June 20, 2018

MMS test
therapy monitoring of patients with colo-rectal or stomach disease or with melanoma

Primary Outcome Measures :
  1. active tumor growth before and after cancer therapy [ Time Frame: up to 36 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with primary diagnosis of cancer

Inclusion Criteria:

  • Clinical diagnosis of colo-rectal cancer
  • Clinical diagnosis of stomach cancer
  • Suspected diagnosis of melanoma

Exclusion Criteria:

  • Colitis ulcerosa
  • Morbus Crohn
  • Cancer in time period two years before
  • Cancer therapy in time period two years before

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02113683

HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie
Berlin, Germany, 13125
Sponsors and Collaborators
MedInnovation GmbH
Helios Klinikum Berlin-Buch
Principal Investigator: Katja Waterstradt, PhD MedInnovation GmbH

Responsible Party: MedInnovation GmbH Identifier: NCT02113683     History of Changes
Other Study ID Numbers: MMS-tm14
First Posted: April 15, 2014    Key Record Dates
Last Update Posted: June 21, 2018
Last Verified: March 2018

Keywords provided by MedInnovation GmbH:
colo-rectal cancer
stomach cancer
MMS test
therapy monitoring

Additional relevant MeSH terms:
Rectal Neoplasms
Stomach Neoplasms
Colorectal Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms, Connective and Soft Tissue
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Stomach Diseases
Colonic Diseases